🔴 Nyxoah is trading 5.8% down in after-hours trading with no company-specific catalyst identified

Nyxoah is trading 5.81% down now at $1.46 after no new company-specific announcement or earnings release was identified for September 16, 2026.

• Earlier September clinical updates included positive ACCCESS trial results and initiation of the BREATHE study.
• The decline may reflect broader risk-off pressure after the Federal Reserve’s rate decision and elevated yields, although the market was mixed.
• Cantor Fitzgerald’s earlier price-target reduction to $6 from $11 is background, not a fresh catalyst.